Royalty Pharma, Q3 2026 Earnings Call Transcript

Royalty Pharma reported 9% third-quarter growth in Portfolio and Royalty Receipts, with year-to-date Royalty Receipts up 12%, and raised its 2026 Portfolio Receipts guidance for the third consecutive quarter to $3.5–$3.55 billion. Management expects 10–11% growth in Royalty Receipts, citing strength across the diversified portfolio. The company invested in royalties on Mimrylo and Zoryve and returned about $590 million to shareholders in the first nine months.

Management sees a robust deal pipeline and expects a dozen potential blockbuster launches to support growth through 2030 and beyond, with development-stage assets potentially adding over $1.7 billion in peak royalties. It cited positive trial and regulatory developments, while pelacarsen’s Phase III failure was a setback; the investment structure is expected to return the funding plus a small gain. R&D co-funding and licensing opportunities from China were identified as growth areas.